Recent studies demonstrate that the molecular elements known to regulate neuronal plasticity in models of learning and memory are also involved in the actions of drugs used for the treatment of depression and bipolar disorder. This includes up-regulation of transcription factors, such as the cAMP response element binding protein and neurotrophic factors, such as brain derived neurotrophic factor. These findings raise the possibility that regulation of neural plasticity in specific neuronal circuits is integrally involved in the therapeutic intervention of mood disorders. Atypical antipsychotic drugs, including clozapine and olanzapine, are also effective for the treatment of bipolar disorder, and are used as add-on medication for unipolar depression. The possibility that these atypical antipsychotic drugs also influence the molecular determinants of synaptic plasticity that are involved in the response to drugs used for the treatment of mood disorders, is discussed. Molecular Psychiatry (2002) 7, S29-S34.
Introduction
Significant advances have been made in our understanding of the molecular and cellular determinants of neural plasticity, particularly the adaptations underlying learning and memory. Among the factors identified to play an important role in neural plasticity is the cyclic AMP response element binding protein (CREB) and brain derived neurotrophic factor (BDNF).
1,2 These factors and related elements may also be involved in the adaptive responses, including responses to stress and psychotropic drugs, in limbic neural circuits. [3] [4] [5] The integrity of CREB and BDNF and the pathways that control them may be critical for normal adaptive responses to, or resilience to the effects of, stress. Disruption of these factors by repeated or severe stress or as a result of genetic vulnerability could contribute to the pathophysiology of mood disorders. Recent studies support this hypothesis, demonstrating that stress down-regulates BDNF and may disrupt CREB function; effects that are opposite to the actions of drugs used for the treatment of mood disorders. The induction of these factors by medications used for the treatment of depression or bipolar disorder may thereby contribute to the appropriate adaptive plasticity and their therapeutic efficacy.
Clinical studies demonstrate that atypical antipsychotic agents are effective for the treatment of bipolar disorder, as well as for unipolar depression (see reviews by Krystal and Keck in this issue). The atypical antipsychotic drugs are antagonists of a number of Correspondence: Dr RS Duman, 34 Park Street, New Haven, CT 06508, USA. E-mail: ronald.dumanȰyale.edu monoamine receptor subtypes, and this has been the focus of studies aimed at understanding the therapeutic action of these agents. However, given the potential role of CREB and BDNF in the actions of antidepressants and mood-stabilizing drugs, it is possible that these factors, or related factors, are also involved in the actions of antipsychotic drugs in the treatment of mood disorders. The purpose of this review is to briefly evaluate the current information on the role of CREB and BDNF in the treatment and pathophysiology of mood disorders, and to discuss the hypothesis that atypical antipsychotic agents may act, in part, via regulation of these mediators of neuronal plasticity and survival.
Role of CREB in mood disorders
The cAMP-CREB signal transduction cascade is known to underlie sustained alterations that occur in cellular and behavioral models of learning and memory. 2, 6 In addition, neurotrophic-factor-dependent survival of neurons is dependent on the functional activity of CREB. 7, 8 CREB is particularly well situated as a convergent transcriptional target of different signal transduction systems (Figure 1 ). This includes phosphorylation and activation of CREB by Ca 2+ -calmodulin-dependent kinase, protein kinase C and ribosomal S6 kinase, as well as cAMP-dependent protein kinase (PKA). 9 CREB may thereby serve as a central integrator of signaling for a variety of extracellular stimuli that influence neuronal plasticity and survival. In addition, the potential for multiple pathways for regulation would provide a mechanism for activating CREB even if there was a malfunction of any single pathway. This type of redun- -dependent protein kinases, activates CREB via phosphorylation of specific amino acids residues. Activation of the cAMP or Ca 2+ signaling pathways may occur via neurotransmitter receptors (R). CREB is a transcription factor and one of the genes regulated by the cAMP-CREB cascade and antidepressant administration is brain derived neurotrophic factor (BDNF). Increased CREB and BDNF could contribute to trophic effects of antidepressants, including synaptic remodeling and increased neurogenesis. dancy would be particularly important for control of such important neuronal functions as plasticity and survival.
Regulation of CREB by antidepressants and moodstabilizing drugs
A role for CREB in the treatment of mood disorders is supported by studies demonstrating that agents used for the treatment of unipolar depression or bipolar disorder up-regulate CREB (Figure 1) . 3, 4 Chronic, but not acute, antidepressant administration, including norepinephrine and serotonin selective reuptake inhibitors, increase CREB expression, phosphorylation and function in limbic brain structures, including hippocampus and cerebral cortex. 10, 11 Long-term administration of lithium or valproate also increases the phosphorylation of CREB. 5 In contrast, CREB is not influenced in these same brain structures by repeated opiate or psychostimulant administration, demonstrating the pharmacological specificity of this effect.
The influence of antipsychotic drug treatment on CREB in limbic structures has also been examined, but these studies have been limited and primarily conducted as pharmacological controls. Repeated administration of a typical antipsychotic drug, haloperidol, did not influence CREB expression or phosphorylation in hippocampus or cerebral cortex, 10, 12 but is reported to increase phosphorylation of CREB in the striatum. 13 A focused series of studies to examine the influence of atypical antipsychotic drugs on CREB in the same limbic structures targeted for antidepressant studies is necessary to examine this hypothesis.
Antidepressant effects of CREB in behavioral models of depression
Although up-regulation of CREB is consistent with the hypothesis that this transcription factor is involved in the therapeutic action of drugs used for the treatment of mood disorders, these data are only correlative. To directly test this hypothesis, the influence of CREB over-expression on forced swim and learned helplessness has been examined. We have used a viralmediated gene transfer approach to express CREB. 14 The results of these studies demonstrate that overexpression of CREB in a small portion of the dentate gyrus of hippocampus is sufficient to produce an antidepressant-like effect in both behavioral models. CREB expression decreased immobility time in the forced swim test and decreased the number of escape failures in learned helplessness. The antidepressant effect of CREB was similar in magnitude to the effects of chemical antidepressant drugs administered systemically. These results demonstrate that expression of CREB in the hippocampus is sufficient to produce an antidepressant effect. Inducible and region-specific transgenic mice that express CREB, or a dominant negative CREB mutant, are being developed to further test this hypothesis.
CREB expression is altered in cerebral cortex of depressed patients
Regulation of CREB by therapeutic agents does not necessitate a role for CREB in the pathophysiology of mood disorders. However, a recent study demonstrates that levels of CREB are altered in postmortem brains of patients with depression. 15 This study demonstrates that levels of CREB immunoreactivity are decreased in the temporal cortex of patients suffering from depression and not receiving medication at the time of death. In addition, there was a significant increase in the level of CREB expression in the cerebral cortex of patients treated with antidepressant at the time of, or for a period shortly before, death. These findings raise the possibility that decreased function or expression of CREB could also contribute to mood disorders. This is consistent with the general hypothesis that disruption of CREB could alter the normal adaptive plasticity that is necessary to respond to stress and other external stimuli. Additional studies will be required to confirm this finding and to determine if down-regulation of CREB can contribute to the formation of mood disorders, or if this is a state-dependent marker. The neuroprotective and survival-enhancing effects of CREB may also contribute to the therapeutic actions of antidepressants and mood stabilizers because neuronal atrophy and cell loss have been observed in patients with mood disorders (see below).
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Role of BDNF in mood disorders
BDNF and other members of the nerve growth factor (NGF) family are critical for the differentiation of neurons during development, but also contribute to the survival and plasticity of neurons in adult brain. 16, 17 BDNF is the most abundantly expressed of the neurotrophic factor family, which also includes NGF, neurotrophin-3 and neurotrophin-4. Expression of BDNF is activity dependent and has been shown to contribute to the synaptic plasticity underlying cellular models of learning and memory. 17 In addition, BDNF expression is increased by neuronal injury such as hypoxia, ischemia and exposure to neurotoxin, and may provide neuroprotective benefit under these circumstances. 16 
BDNF expression is up-regulated by antidepressant treatment
If structural alterations and synaptic remodeling are involved in the pathophysiology of mood disorders, it is possible that the actions of drugs used for the treatment of these disorders would include effects that would oppose or reverse these changes. Up-regulation of neurotrophic factors would be one mechanism by which these drugs could influence these structural alterations. Preclinical studies support this possibility. Repeated antidepressant administration, including NE or 5-HT selective reuptake inhibitors, increases the expression of BDNF in hippocampus. 18, 19 Electroconvulsive seizures, which produce the greatest effect of the treatments tested, as well as administration of a monoamine oxidase inhibitor, also increase BDNF expression in frontal cortex. 18 Up-regulation of BDNF is dependent on repeated and long-term treatment, consistent with the time course for the therapeutic action of antidepressant drugs. The pharmacological specificity of this effect has also been demonstrated in that morphine or cocaine administration does not influence BDNF expression in hippocampus or frontal cortex. Antidepressant treatment also blocks the down-
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Molecular Psychiatry regulation of BDNF by exposure to immobilization stress. 18 The influence of medications used for the treatment of bipolar disorder and schizophrenia on neurotrophic factor expression has also been examined. Preliminary studies demonstrate that long-term administration of lithium increases the expression of BDNF in cerebral cortex. 10 Repeated administration of haloperidol results in a small decrease in levels of BNDF expression in hippocampus, frontal cortex, amygdala and ventral tegmental area. 18, 20, 21 One of these studies demonstrates that acute haloperidol treatment (3 days) decreases BDNF immunostaining in cell bodies and fibers in these brain regions, but that after long-term treatment (21 days), the expression in cell bodies, but not fibers, is reversed. 21 In contrast, one study has reported that acute or repeated administration of the atypical antipsychotic, clozapine, does not influence the expression of BDNF in cortex or hippocampus. 22 Expression of NGF in these brain regions is reported to be increased by repeated (14-day) administration of haloperidol. 23 Much more study will be required to determine if the regulation of neurotrophic factors contributes to the therapeutic actions, or side effects, of antipsychotic agents. Additional studies are also needed to confirm the effect of lithium on BDNF expression and to examine the influence of other mood stabilizers and atypical antipsychotic drugs. It will also be important to determine if these agents block the down-regulation of BNDF by stress.
BDNF has antidepressant effects in behavioral models of depression
Studies have been conducted to extend these correlative findings on the expression of BDNF by antidepressant treatment. These studies have been carried out by intracerebral infusion of recombinant BDNF. Unlike CREB, recombinant BDNF produces cellular effects by acting at its extracellular receptor, TrkB. Administration of BDNF via osmotic minipump, for 7 days into the midbrain, has been shown to have an antidepressant effect in the forced swim and learned helplessness paradigms. 24 The antidepressant effects of the midbrain infusion of BDNF are thought to result from enhancement of 5-HT neurotransmission. This is consistent with reports that BDNF is a potent neurotrophic factor for 5-HT neurons. 25 The influence of BDNF infusions directly into the hippocampus, where antidepressants consistently increase BDNF, has also been examined. In a preliminary report, direct infusion of BDNF into either the dentate gyrus granule cell layer or CA3, but not CA1, pyramidal cell layer of hippocampus produced an antidepressant effect in both the learned helplessness and forced swim models of depression. 26 A similar effect was observed with infusion of NT-3, but not NGF. This effect appears to be somewhat specific in that there was no significant effect of BDNF or NT-3 on locomotor activity. The most surprising aspect of this study is that the antidepressant responses were observed after a single, localized infusion of BDNF or NT-3 into a small portion of the hippocampus. In addition, this effect was observed 3 days after neurotrophic factor infusion and lasted for at least 10 days. These results demonstrate that a localized, single infusion of BDNF or NT-3 is capable of producing antidepressant effects that are similar in magnitude to repeated systemic administration of a chemical antidepressant.
Structural alterations in the pathophysiology and treatment of mood disorders
The regulation of BDNF by stress and antidepressant administration suggests that structural alterations or remodeling of limbic circuits may also occur. This possibility is supported by preclinical and clinical studies of stress, mood disorders and antidepressants.
Neuronal atrophy and cell loss in mood disorders
Preclinical studies demonstrate that exposure of experimental animals to repeated stress produces atrophy, or even death in severe cases, of CA3 pyramidal neurons and decreases neurogenesis in adult brain (Figure 2) . [27] [28] [29] The expression of BDNF, which could contribute to neuronal atrophy and cell loss, is also reported to be dramatically down-regulated by stress. 30 Clinical studies demonstrate that patients with mood disorders also exhibit atrophy or cell death in limbic structures. Brain-imaging studies report that the size of the hippocampus is reduced in patients with depression or posttraumatic stress disorders. [31] [32] [33] The volume of the subgenual prefrontal cortex is decreased in patients with familial depression or bipolar disorder. 34 The number of neurons and glia are also reported to be decreased in the temporal cortex of patients with unipolar depression or bipolar disorder. 35, 36 The atrophy and loss of neurons in limbic brain regions demonstrate that there are structural, as well as neurochemical, imbalances in stress-related mood disorders. These structural abnormalities could be due to a number of different factors, including excess levels of adrenal-glucocorticoids, glutamatergic excitotoxicity, viral infection, excitoxins, hypoxiaischemia or vulnerability to these factors as a result of genetic variation. 28, 29 The cumulative effects of exposure to one or more of these factors over the course of life could also underlie individual variability to stress. 3, 4 However, additional studies will be required to determine the extent of these structural abnormalities in mood disorders and to determine if they are markers of trait or state.
Antidepressant treatment increases adult neurogenesis
Neurogenesis has been reported in selected regions of the adult brains of a variety of species, including rodents, birds and primates. 37, 38 In mammals, adult neurogenesis is localized to the subventricular zone, where cells migrate via the rostral migratory pathway to the olfactory bulb, and the subgranular zone, which gives rise to cells in the granule cell layer of the hippocam-pus. The proliferation and survival of neurons in adult hippocampus is extremely dynamic and is up-regulated by exercise, environmental enrichment, hippocampal-dependent learning and estrogen. In contrast, stress decreases neurogenesis in hippocampus of adult rodent and non-human primates. 27, 39 This effect could contribute to the decreased volume of the hippocampus observed in patients with depression or posttraumatic stress disorder, although the significance of adult neurogenesis in adult human hippocampus has not yet been established.
These findings, combined with the reports of structural abnormalities in mood disorder patients, have prompted studies to determine if antidepressant treatment influences adult neurogenesis. Repeated antidepressant administration has been found to significantly increase the rate of cell proliferation in hippocampus (Figure 2) . 40 This includes repeated, but not acute, administration of NE or 5-HT selective reuptake inhibitors. In this study, repeated administration of haloperidol did not influence neurogenesis, and repeated administration of morphine is reported to decrease hippocampal neurogenesis. 41 We have also found that administration of fluoxetine blocks the down-regulation of neurogenesis resulting from exposure to learned helplessness. 40 Antidepressant induction of adult neurogenesis has also been reported by several other laboratories. [42] [43] [44] In addition, long-term lithium treatment increases hippocampal neurogenesis. 45 These findings support the hypothesis that up-regulation of hippocampal neurogenesis could oppose the effects of stress and could reverse the atrophy observed in the brains of depressed patients. However, atrophy of CA3 neurons may contribute to the reduction in hippocampal volume that has been observed. Additional postmortem studies of the number and size of hippocampal neurons in both the dentate gyrus and CA3 pyramidal cell layers will be required to address this question.
There are studies demonstrating that chronic administration of haloperidol influences adult neurogenesis, with one study reporting an increase and the other a decrease. 46, 47 However, either the high dose of haloperidol used or the early developmental stage chosen for testing complicates these studies. Additional studies of atypical antipsychotic drugs on either the basal rate of neurogenesis or on the down-regulation of neurogenesis in response to stress are warranted.
The roles of CREB and BDNF in the regulation of neurogenesis are being examined. Preliminary studies demonstrate that pharmacological activation of the cAMP-CREB cascade (ie, administration of rolipram) increases hippocampal neurogenesis. 48 In addition, transgenic overexpression of a dominant negative mutant of CREB decreases neurogenesis in adult mouse hippocampus. 49 These findings are consistent with the hypothesis that CREB could mediate the action of antidepressant and mood-stabilizing drugs on neurogenesis. The influence of BDNF on the proliferation, as well as differentiation and survival of, hippocampal neurons is also being examined.
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CA3 pyramidal cell atrophy
There is one study that has examined the influence of antidepressant treatment on the atrophy of CA3 pyramidal neurons in response to stress. This study reports that repeated administration of an atypical antidepressant, tianeptine, blocks the atrophy of CA3 pyramidal neurons that occurs in response to restraint stress. 50 Fluoxetine treatment was examined in this same study, but did not influence CA3 atrophy. Additional studies of antidepressants, as well as moodstabilizing and antipsychotic drugs are needed to further elucidate the influence of these different classes of therapeutic agents on CA3 neuronal atrophy. A combination of CA3 dendritic atrophy and decreased neurogenesis could underlie the decreased hippocampal volume observed in patients with mood disorders.
Future perspectives
The data supporting a role for CREB and BDNF in the actions of medications used for the treatment of mood disorders have several implications. Firstly, these findings suggest that drugs that activate the cAMP cascade or alternate pathways that influence CREB have potential therapeutic agents. Potential targets include NE or 5-HT receptors that are positively coupled to the cAMP pathway and selective inhibitors of PDE4 isozymes that do not have the side effects of rolipram. 3, 4 A second important implication of this work is that it provides a framework for understanding the actions of other agents used for the treatment of mood disorders. This includes the atypical antipsychotic drugs used for unipolar depression and bipolar disorder. Thirdly, these studies support the hypothesis that mood disorders can result from a structural alteration or remodeling, as well as a neurochemical imbalance. The elucidation of the extent and cause of these cellular and synaptic changes is only limited by the resources and technological approaches brought to bear on this question. With this in mind, we can expect to see significant advances in the coming years.
